FYARRO
DEAD

Serial Number

88599810

Owner

AADi Bioscience, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Aug 30, 2019

Add to watchlist:

No watchlists yet
View on USPTO

FYARRO Trademark

Serial Number: 88599810

FYARRO is a trademark filed by AADi Bioscience, Inc. on August 30, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

AADi Bioscience, Inc. (13 trademarks)

1343 Luna Vista Dr
Pacific Palisades, CA 90272

Entity Type: 03

Trademark Details

Filing Date

August 30, 2019

Registration Date

Not Registered

Published for Opposition

July 28, 2020

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, and acute respiratory disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases

Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 23, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 23, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 22, 2023 EXRA
SOU EXTENSION 5 GRANTED
Mar 21, 2023 EX5G
SOU EXTENSION 5 FILED
Mar 17, 2023 EXT5
SOU TEAS EXTENSION RECEIVED
Mar 17, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 23, 2022 EXRA
SOU EXTENSION 4 GRANTED
Sep 21, 2022 EX4G
SOU EXTENSION 4 FILED
Sep 21, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 21, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2022 EXRA
CORRECTED NOA E-MAILED
May 7, 2022 NOAC
SOU EXTENSION 3 GRANTED
May 6, 2022 EX3G
DIVISIONAL PROCESSING COMPLETE
May 6, 2022 DPCC
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 11, 2022 TROA
ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
Apr 5, 2022 INCD
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 1, 2022 AITU
SOU EXTENSION 3 FILED
Mar 22, 2022 EXT3
DIVISIONAL REQUEST RECEIVED
Mar 21, 2022 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Mar 21, 2022 ERTD
SOU TEAS EXTENSION RECEIVED
Mar 21, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 22, 2021 EXRA
SOU EXTENSION 2 GRANTED
Sep 20, 2021 EX2G
SOU EXTENSION 2 FILED
Sep 20, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 20, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 25, 2021 EXRA
SOU EXTENSION 1 GRANTED
Feb 23, 2021 EX1G
SOU EXTENSION 1 FILED
Feb 23, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 23, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 22, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 28, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jul 28, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 8, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 24, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2020 CRFA
ASSIGNED TO LIE
Jun 16, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 11, 2019 GNRN
NON-FINAL ACTION E-MAILED
Dec 11, 2019 GNRT
NON-FINAL ACTION WRITTEN
Dec 11, 2019 CNRT
ASSIGNED TO EXAMINER
Dec 4, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 12, 2019 NWOS
NEW APPLICATION ENTERED
Sep 3, 2019 NWAP